Shenzhen International Holdings Limited
深圳國際控股有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 00152)

CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTORS AND CHANGE IN COMPOSITION OF THE RELEVANT SPECIALISED COMMITTEES OF THE BOARD

The Board announces that, with effect from 30 July 2026:

(i) Dr. Cheng Chuange has been appointed as an Independent Non-executive Director, the chairman of the Nomination Committee and a member of the Audit Committee;

(ii) Mr. Pan Chaojin has resigned from his positions as an Independent Non-executive Director, the chairman of each of the Nomination Committee and the Remuneration and Appraisal Committee, and a member of the Audit Committee;

(iii) Dr. Wang Guowen has been appointed as the chairman of the Remuneration and Appraisal Committee; and

(iv) Professor Ding Chunyan has been appointed as a member of the Remuneration and Appraisal Committee.

(1) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board of directors (the "**Board**") of Shenzhen International Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that Dr. Cheng Chuange ("**Dr. Cheng**") has been appointed as an independent non-executive director of the Company (the "**Independent Non-executive Director**"), the chairman of the nomination committee (the "**Nomination Committee**") and a member of the audit committee of the Company (the "**Audit Committee**"), with effect from 30 July 2026.

The biographical details of Dr. Cheng are as follows:

Dr. Cheng, aged 61, holds a Bachelor's degree in Philosophy from Zhengzhou University, a Master's degree in Philosophy and a Doctoral degree in Economics from Wuhan University, and possesses the qualification of a senior economist. Dr. Cheng is currently a member of the 13th Henan Provincial Committee of the Chinese People's Political Consultative Conference, the Supervisor of the Hong Kong Small and Medium Listed Companies Association, and a non-executive director of Henan United Information Technology Co., Ltd.

Dr. Cheng has over 30 years of extensive experience in financial and corporate management, with his professional expertise spanning multiple sectors from commercial banking, investment banking, securities to insurance. He has accumulated profound senior management and practical experience in both the Mainland and Hong Kong markets. Dr. Cheng previously served as the deputy chief executive officer and executive director of BOCOM International Holdings Company Limited (whose shares are listed on the main board of The Stock Exchange of Hong Kong Limited, stock code: 3329) and a non-executive director of China BOCOM Insurance Company Limited. The Board is of the view that Dr. Cheng, having extensive experience in capital operations, mergers and acquisitions, and management experience of listed company, is expected to bring valuable opinion and guidance to the Group's development.

Dr. Cheng has entered into a director's service contract with the Company for a term of three years commencing on 30 July 2026 and will be subject to retirement and re-election at the next annual general meeting of the Company in accordance with the Memorandum of Association and Bye-laws of the Company. Pursuant to the director's service contract entered into with Dr. Cheng, he is entitled to receive an annual director's fee of HK$350,000, which was determined by the Board based on the recommendation of the remuneration and appraisal committee of the Company (the "**Remuneration and Appraisal Committee**") with reference to his qualification, experience and the estimated amount of time to be spent by him on the Company's matters.

Save as disclosed above and as at the date of this announcement, Dr. Cheng does not hold or has not held any position with the Group and does not hold or has not held any directorships in other listed companies in the last three years. He does not have any relationship with any Directors, senior management, substantial shareholders and/or controlling shareholders (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")) of the Company.

As at the date of this announcement, Dr. Cheng does not have or is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Dr. Cheng has confirmed that: (i) he meets all the independence criteria as set out in Rule 3.13 (1) to (8) of the Listing Rules; (ii) he has no financial or other interest in the business of the Group, whether past or present, and has no connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence at the time of his appointment.

Save as disclosed above, the Company considers that in relation to the appointment of Dr. Cheng as an Independent Non-executive Director, there is no other information which is required to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules, and there is no other matter in relation to his appointment which needs to be brought to the attention of the shareholders of the Company.

The Board would like to welcome Dr. Cheng to join the Board.

(2) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board announces that, as Mr. Pan Chaojin ("**Mr. Pan**") has served as an Independent Non-executive Director for a period of 6 years, in accordance with the Company's relevant internal guideline, Mr. Pan has resigned from his positions as an Independent Non-executive Director, the chairman of each of the Nomination Committee and the Remuneration and Appraisal Committee, and a member of the Audit Committee, with effect from 30 July 2026.

Mr. Pan has confirmed that he has no disagreement with the Board and there is no other matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company.

Mr. Pan has provided the Group with a wide range of valuable opinions and guidance in various aspects, including the business development and corporate governance of the Group, during his tenure of service, from which the Group has benefited substantially. The Board would like to take this opportunity to extend its heartfelt gratitude to Mr. Pan for his contribution to the Board.

(3) CHANGE IN COMPOSITION OF THE RELEVANT SPECIALISED COMMITTEES OF THE BOARD

In view of the above changes of Independent Non-executive Directors, the Board further announces that, with effect from 30 July 2026, the composition of each of the Audit Committee, Nomination Committee and Remuneration and Appraisal Committee has been changed as follows:

Audit Committee:
Dr. Cheng has been appointed as a member of the committee, and Mr. Pan has ceased to be a member of the committee. Following the change, the members of the Audit Committee are Dr. Zeng Zhi (Chairman), Dr. Wang Guowen and Dr. Cheng Chuange.

Nomination Committee:
Dr. Cheng has been appointed as the chairman of the committee, and Mr. Pan has ceased to be the chairman of the committee. Following the change, the members of the Nomination Committee are Dr. Cheng Chuange (Chairman), Mr. Wang Peihang and Professor Ding Chunyan.

Remuneration and Appraisal Committee:
Dr. Wang Guowen has been appointed as the chairman of the committee, Professor Ding Chunyan has been appointed as a member of the committee, and Mr. Pan has ceased to be the chairman of the committee. Following the change, the members of the Remuneration and Appraisal Committee are Dr. Wang Guowen (Chairman), Mr. Cai Xiaoping and Professor Ding Chunyan.

By Order of the Board
Shenzhen International Holdings Limited
Liu Wangxin
Joint Company Secretary

30 July 2026

As at the date of this announcement, the Board consists of Mr. Li Haitao, Mr. Liu Zhengyu, Mr. Wang Peihang and Ms. Liu Xiuli as executive directors, Mr. Cai Xiaoping as a non-executive director and Dr. Zeng Zhi, Dr. Wang Guowen, Professor Ding Chunyan and Dr. Cheng Chuange as independent non-executive directors.